Pharmacoeconomic review report Empagliflozin (Jardiance) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Cost effectiveness.

Physical Description:

1 online resource (ii, 13 pages)

Other Title:

Pharmacoeconomic review report Empagliflozin

Place of Publication:

Ottawa (ON) : CADTH, 2015.

Summary:

Empagliflozin (Jardiance) is a once-daily oral antidiabetic drug belonging to the sodium glucose cotransporter-2 (SGLT-2) inhibitor class. It promotes urinary glucose excretion. This review by the CADTH Common Drug Review (CDR) will focus on the following indication: 1. For adults with type 2 diabetes mellitus, to improve glycemic control in combination with metformin and a sulfonylurea when diet, exercise, and dual therapy (with metformin plus sulfonylurea) do not provide adequate glycemic control. The recommended dose of empagliflozin is 10 mg once daily. This dose can be increased to 25 mg once daily in patients who tolerate empagliflozin but need additional glycemic control. The manufacturer submitted a price of 2.6177 per 10 mg or 25 mg tablet (2.62 daily). The manufacturer is requesting a listing in a manner similar to other SGLT-2 inhibitors and/or dipeptidyl peptidase (DPP)-4 inhibitors.

Notes:

Description based on publisher supplied metadata and other sources.